Dual specificity mitogen-activated protein kinase kinase 7 (MKK7)

Dual specificity mitogen-activated protein kinase kinase 7, commonly known as MKK7 or MAP2K7, is a pivotal enzyme within the mitogen-activated protein kinase (MAPK) signaling cascade [1, 5]. It acts as a primary activator of the c-Jun N-terminal kinase (JNK) pathway by specifically phosphorylating the threonine residues within the JNK activation loop in response to environmental stresses and proinflammatory cytokines [1, 7]. This kinase is essential for translating various cellular stress signals into biological responses such as apoptosis, cell proliferation, and differentiation [2, 5]. In the context of disease, MKK7 is implicated in the progression of several cancers, including T-cell acute lymphoblastic leukemia and breast cancer, where its aberrant activity can promote tumor cell survival [4, 8]. It also plays significant roles in inflammation-related conditions like COPD and neurological disorders such as schizophrenia [2, 3]. Therapeutically, MKK7 is being explored as a target for small-molecule and peptide-based inhibitors, such as DTP3, which aim to disrupt its interaction with regulatory proteins like GADD45β to selectively modulate the JNK pathway [4, 9]. However, drug development must navigate potential safety concerns regarding cardiac function and immunity, given the protein's homeostatic roles in these tissues [4, 7].

Other names

MAP2K7MAPKK7JNK-activating kinase 2c-Jun N-terminal kinase kinase 2 (JNKK 2)MAPK/ERK kinase 7 (MEK 7)SAPKK-4PRKMK7

Disruption of the GADD45β/MKK7 protein-protein interaction (e.g., DTP3); ATP-competitive inhibition of the kinase catalytic domain; Allosteric modulation of the kinase activity.